为什么华法林在心房颤动患者中未得到充分利用？ - Suppr

Suppr

超能文献

Why is warfarin underutilized in patients with atrial fibrillation?

作者信息

Flaker Greg C, Schutz John

机构信息

University of Missouri, Columbia, One Hospital Drive, DC034.00, Room MC314, Columbia, MO 65212, USA.

出版信息

J Interv Card Electrophysiol. 2004;10 Suppl 1:21-5. doi: 10.1023/B:JICE.0000011342.26830.5f.

DOI:10.1023/B:JICE.0000011342.26830.5f

PMID:14739736

Abstract

摘要

相似文献

Why is warfarin underutilized in patients with atrial fibrillation?为什么华法林在心房颤动患者中未得到充分利用？

J Interv Card Electrophysiol. 2004;10 Suppl 1:21-5. doi: 10.1023/B:JICE.0000011342.26830.5f.

The risks and benefits of antithrombotic therapy in chronic atrial fibrillation.慢性心房颤动抗栓治疗的风险与获益

Med J Aust. 1996 May 20;164(10):624-6. doi: 10.5694/j.1326-5377.1996.tb122211.x.

Anticoagulation and atrial fibrillation. Putting the results of clinical trials into practice.抗凝与心房颤动。将临床试验结果应用于实践。

West J Med. 1995 Aug;163(2):145-52.

Pro: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Why warfarin should really be the drug of choice for stroke prevention in elderly patients with atrial fibrillation.正方观点：“华法林应该是老年房颤患者血栓预防的首选药物”。为什么华法林确实应该成为老年房颤患者预防中风的首选药物。

Thromb Haemost. 2008 Jul;100(1):14-5. doi: 10.1160/TH08-06-0344.

Barriers to the use of warfarin: potential solutions.华法林使用的障碍：潜在解决方案。

J Interv Card Electrophysiol. 2004;10 Suppl 1:17-20. doi: 10.1023/B:JICE.0000011341.67214.2e.

Barriers to anticoagulation in patients with atrial fibrillation: changing physician-related factors.心房颤动患者抗凝治疗的障碍：不断变化的医生相关因素。

Stroke. 2008 Jan;39(1):7-9. doi: 10.1161/STROKEAHA.107.496554. Epub 2007 Nov 29.

The need for new oral anticoagulants in clinical practice.临床实践中对新型口服抗凝剂的需求。

J Cardiovasc Med (Hagerstown). 2009 Aug;10(8):605-9. doi: 10.2459/JCM.0b013e32832e4954.

Re: The Clinical Quality Improvement Network (CQIN) Investigators. Thromboembolic prophylaxis in 3,575 hospitalized patients with atrial fibrillation. 1998;14:695-702.

Can J Cardiol. 2000 Jan;16(1):99.

Quality of anticoagulation control in atrial fibrillation.心房颤动抗凝控制的质量

Lancet. 2010 Sep 18;376(9745):935-7. doi: 10.1016/S0140-6736(10)61305-0.

Warfarin therapy for atrial fibrillation in general practice--is bleeding risk underestimated?基层医疗中用于心房颤动的华法林治疗——出血风险是否被低估了？

Tidsskr Nor Laegeforen. 2014 Jan 28;134(2):175-9. doi: 10.4045/tidsskr.13.0626.

引用本文的文献

Barriers to warfarin use for stroke prevention in patients with atrial fibrillation in Hong Kong.香港心房颤动患者中预防中风使用华法林的障碍。

Clin Cardiol. 2013 Mar;36(3):166-71. doi: 10.1002/clc.22077. Epub 2012 Nov 14.

Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin.羟基香豆素代谢物能强烈抑制 S-华法林的 CYP2C9 代谢。

Chem Res Toxicol. 2010 May 17;23(5):939-45. doi: 10.1021/tx1000283.

Anticoagulation treatment for the reduction of stroke in atrial fibrillation: a cohort study to examine the gap between guidelines and routine medical practice.用于降低心房颤动患者中风风险的抗凝治疗：一项队列研究，以检验指南与常规医疗实践之间的差距。

J Thromb Thrombolysis. 2007 Aug;24(1):65-72. doi: 10.1007/s11239-006-0002-8. Epub 2007 Jan 27.

本文引用的文献

Thromboembolism associated with auricular fibrillation; continuous anticoagulant therapy.与心房颤动相关的血栓栓塞；持续抗凝治疗。

J Am Med Assoc. 1950 Sep 9;144(2):97-100. doi: 10.1001/jama.1950.02920020017005.

SYSTEMIC EMBOLISM AND ANTICOAGULANT PROPHYLAXIS IN RHEUMATIC HEART DISEASE.风湿性心脏病中的系统性栓塞与抗凝预防

Br Med J. 1964 May 9;1(5392):1209-12. doi: 10.1136/bmj.1.5392.1209.

Chronic anticoagulant therapy in recurrent embolism of cardiac origin.心脏源性复发性栓塞的长期抗凝治疗。

Ann Intern Med. 1953 Feb;38(2):278-87. doi: 10.7326/0003-4819-38-2-278.

A study of the beneficial effects of anticoagulant therapy in congestive heart failure.一项关于抗凝治疗在充血性心力衰竭中的有益作用的研究。

Ann Intern Med. 1952 Nov;37(5):867-87. doi: 10.7326/0003-4819-37-5-867.

A comparison of rate control and rhythm control in patients with atrial fibrillation.心房颤动患者心率控制与节律控制的比较。

N Engl J Med. 2002 Dec 5;347(23):1825-33. doi: 10.1056/NEJMoa021328.

ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology.美国心脏病学会/美国心脏协会/欧洲心脏病学会心房颤动患者管理指南：执行摘要。美国心脏病学会/美国心脏协会实践指南工作组和欧洲心脏病学会实践指南与政策会议委员会（心房颤动患者管理指南制定委员会）报告：与北美心脏起搏和电生理学会合作制定。

J Am Coll Cardiol. 2001 Oct;38(4):1231-66. doi: 10.1016/s0735-1097(01)01587-x.

Are the results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice?关于心房颤动患者抗凝治疗的随机对照试验结果能否推广至临床实践？

Arch Intern Med. 2001 Jun 11;161(11):1443-7. doi: 10.1001/archinte.161.11.1443.

Antithrombotic therapy in atrial fibrillation.

Chest. 2001 Jan;119(1 Suppl):194S-206S. doi: 10.1378/chest.119.1_suppl.194s.

Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association.缺血性卒中的一级预防：美国心脏协会卒中委员会给医疗专业人员的声明

Stroke. 2001 Jan;32(1):280-99. doi: 10.1161/01.str.32.1.280.

Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation.医疗保险受益的慢性心房颤动患者抗血栓治疗使用不足的不良后果及预测因素

Stroke. 2000 Apr;31(4):822-7. doi: 10.1161/01.str.31.4.822.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验